What happens when the Yervoy patent expires?

As of now, the Yervoy [1] (ipilimumab) patent is set to expire in 2025, according to data from DrugPatentWatch.com [2]. Yervoy is a monoclonal antibody cancer treatment, primarily used to treat melanoma and other skin cancers.

Can biosimilars enter the market before or after patent expiry?

Biosimilars can only enter the market after the patent for the original drug has expired [3]. In the US, the Affordable Care Act of 2010 allowed biosimilars to come to market after a 12-year exclusivity period, which is typically the duration of the patent for the original biologic. Yervoy's patent expires in 2025, so biosimilars can enter the market around that time, assuming no further patents are granted for extensions.

Who manufactures biosimilars for Yervoy?

Several companies are working on developing biosimilars for Yervoy, including Eli Lilly, Pfizer, and Amgen [4][5]. While these companies are likely to receive FDA approval for their Yervoy biosimilars in time for the patent expiry, the exact timeline might be subject to change based on ongoing clinical trials, regulatory considerations, and any unforeseen challenges.

What are the implications of Yervoy patent expiry for patients?

When Yervoy's patent expires, biosimilars can enter the market, offering patients more choices and potentially more affordable access to a similar drug. Biosimilars are regulated by the FDA to demonstrate comparable efficacy and safety to the original biologic [6]. However, patients may need to discuss the specific characteristics of each biosimilar with their healthcare providers to ensure the best treatment plan.

Sources:

[1] - Data from Yervoy patent, as reported by DrugPatentWatch.com
[2] - DrugPatentWatch.com - ipilimumab patent status
[3] - FDA - Biosimilar Drug Development and Approval Process
[4] - Eli Lilly's Lipimumab biosimilar in development
[5] - Pfizer's M7824, a PD-1/LAG-3 antagonist targeting combination with an anti-CTLA4 mAb, like Yervoy
[6] - FDA - Biosimilar Interchangeability and Substitution